What Soliqua 100/33 Treats: Main Uses and Benefits

Soliqua 100/33 is commonly used in adults with Type 2 Diabetes Mellitus in situations where the current approach is not achieving the desired therapeutic support. The medicine is indicated for use when blood sugar levels, such as A1C, remain uncontrolled despite other treatments.

The primary therapeutic objective is to assist in maintaining glucose stability and managing high blood sugar. This involves addressing both Fasting Plasma Glucose (FPG) levels and Post-Meal Glucose (PPG) spikes. The medication is used to help manage chronic hyperglycemia in patients who require additional supportive assistance for sustained blood sugar control.

The combination approach is intended to help manage the physiological aspects of persistent chronic hyperglycemia. Used as an adjunct to diet and exercise, this therapeutic method may assist with maintaining glycemic stability for patients with complex chronic care needs.

---

Quick Fact: Relief for Inadequate Control
Therapeutic Use	Management of Type 2 Diabetes Mellitus when current therapy fails to meet glucose goals.
Symptom Domains	Elevated Fasting Plasma Glucose (FPG) and Post-Meal Glucose (PPG) spikes.
Patient Benefit	Supports the simplification of the treatment regimen and provides assistance in managing blood sugar levels.

---

Who Can and Cannot Use Soliqua 100/33?

The population eligibility for Soliqua 100/33 is strictly defined by regulatory documentation, which outlines the approved users and specific contraindications. The medicine is indicated solely for adults with Type 2 Diabetes Mellitus.

Use Restrictions and Exclusions

Category	Regulatory Status
Absolute Contraindication	Contraindicated during episodes of hypoglycemia or in patients with known serious hypersensitivity to any component.
Disease-Type Exclusion	Must not be used for Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
Organ Function Limitations	Not recommended for patients with severe renal impairment or End-Stage Renal Disease (ESRD).
Gastrointestinal Status	Not recommended for patients with severe gastroparesis or other severe gastrointestinal disease.
Concomitant Therapy	Not recommended for use in combination with any other GLP-1 receptor agonist.

Age and Reproductive Status

Safety and efficacy have not been established in pediatric patients (under 18). Use is generally not recommended during pregnancy. For older adults (over 75 years), therapeutic experience is considered limited.

Interactions with other medicines and products

Interaction Scope

Category	Description / Entity
Medicinal product categories with documented interactions	Other antidiabetic agents (e.g., Sulfonylureas, other insulins), Thiazolidinediones (TZDs), Antiadrenergic drugs (e.g., Beta-blockers), agents that may increase or decrease blood glucose.
Specific interacting medicines (if explicitly listed)	Oral Contraceptives, Acetaminophen, other GLP-1 receptor agonists.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic (PD) Interaction: Additive effect on blood glucose or masking of hypoglycemia signs. Pharmacokinetic (PK) Interaction: Lixisenatide component delays gastric emptying, potentially reducing the absorption rate of orally co-administered medicines.
Timing-based interaction rules (if applicable)	Oral Contraceptives: Must be taken at least 1 hour before Soliqua 100/33 or 11 hours after. Oral Medications (Rapid Action): Should be taken at least 1 hour before Soliqua 100/33.
Population-specific interaction notes (if applicable)	Severe Renal Impairment (ESRD) or Severe Gastrointestinal Disease (e.g., Gastroparesis): Use is not recommended.
Interaction-related restrictions	Do not co-administer with any other product containing a GLP-1 receptor agonist. Concomitant use with Sulfonylureas is formally discouraged due to the documented increase in hypoglycemia risk.

---

Interaction Classifications (High-Level)

Classification	Description / Entity
Interaction severity classification	Contraindicated/Not Recommended: Other GLP-1 RAs, Sulfonylureas, severe renal/GI impairment. Clinically Significant / Caution Required: Thiazolidinediones (TZDs) due to the documented risk of fluid retention and potential heart failure exacerbation; antiadrenergic drugs due to the documented risk of masking hypoglycemia symptoms.
Regulatory basis	FDA Prescribing Information, EMA Summary of Product Characteristics (SmPC).

---

Official interaction statements:

• Co-administration with any other GLP-1 receptor agonist product is formally restricted.
• The use with Thiazolidinediones is documented to potentially cause fluid retention, which may lead to or worsen heart failure.
• Alcohol consumption is documented to potentiate the glucose-lowering effect of the medicine, increasing the official risk of hypoglycemia.
• Antiadrenergic drugs may formally reduce the awareness of hypoglycemia symptoms.
• The effect of Lixisenatide on gastric emptying requires timing separation for certain oral medicines, including oral contraceptives and those requiring rapid absorption like acetaminophen.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product's interaction profile through documented pharmacodynamic synergism with other blood-glucose-lowering agents and a pharmacokinetic effect on the absorption of oral medicines. This dual structure necessitates specific timing separation rules for numerous oral drugs and formal restrictions against combining the fixed-ratio product with certain other antidiabetic agents to manage the documented interaction risks.

Soliqua 100/33 is a fixed-ratio combination product containing two pharmacologically distinct agents: insulin glargine and lixisenatide.

Insulin glargine, a long-acting insulin analog, is a receptor agonist that binds to the insulin receptor (IR) present on the membranes of target tissues, primarily skeletal muscle, adipocytes, and hepatocytes. Upon binding, the IR undergoes autophosphorylation, initiating an intracellular cascade involving the insulin receptor substrate (IRS) proteins and the phosphatidylinositol 3-kinase (PI3K) pathway. This signaling drives the translocation of glucose transporter type 4 (GLUT4) vesicles to the cell surface, promoting the uptake of circulating glucose into peripheral cells. Concurrently, it suppresses hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis.

Lixisenatide, a glucagon-like peptide-1 (GLP-1) analog, acts as a receptor agonist at the GLP-1 receptor located on pancreatic beta-cells.

Activation of this G-protein coupled receptor stimulates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) levels. This cAMP-mediated pathway enhances glucose-dependent insulin secretion from the beta-cells. Furthermore, lixisenatide reduces glucagon secretion from pancreatic alpha-cells and delays gastric emptying, thereby modulating postprandial glucose flux into the systemic circulation. The combined mechanistic actions result in integrated system-level modulation of glucose homeostasis by targeting both insulin-dependent peripheral uptake and GLP-1-mediated beta-cell function and counter-regulatory hormone control.

Administration Overview

Soliqua 100/33 is administered as a subcutaneous injection. It is typically injected once daily into the fat layer just under the skin of the abdomen, thigh, or upper arm. It is important to rotate injection sites within the chosen area for each dose to reduce the risk of skin changes such as lumps or pitting.

Using the SoloStar Pen

The medication is provided in a pre-filled, disposable multidose pen. Each pen contains a combination of two active ingredients. The pen allows for the selection of a specific number of units as determined by a healthcare provider.

Preparation and Inspection

Before use, the pen should be checked to ensure the liquid is clear and colorless. If the solution appears cloudy, colored, or contains particles, the pen should not be used. A new, sterile needle must be attached for every injection to maintain sterility and prevent needle blockage.

Priming and Injection

A safety test, or priming, is performed before each injection to ensure the pen and needle are working correctly and to remove air bubbles. Once the dose is dialed and the needle is inserted into the skin, the injection button is pressed and held until the dose counter returns to zero. It is necessary to wait several seconds before withdrawing the needle to ensure the full dose has been delivered.

Storage and Handling

Proper storage is essential for maintaining the stability of the medication. Unopened pens should be kept in a refrigerator, while pens currently in use can typically be kept at room temperature for a limited number of days. Regardless of storage, pens must be kept away from direct heat and light. After use, needles should be disposed of in a puncture-resistant sharps container.

Soliqua 100/33: Recent Clinical Evidence

Research Evidence: Adults Not Yet Using Insulin (Insulin-Naive)

The research for this combination therapy rests on short-term (30-week) Randomized Controlled Trials (RCTs) designed to examine the fixed-ratio combination in insulin-naive adults whose blood sugar levels met the study criteria for inadequate glycemic control on oral medicines alone. Researchers primarily measured changes in the long-term glucose biomarker, HbA1c, and monitored shifts in Body Weight. Findings described that when the combination was studied, the change in the A1C biomarker was compared to the reported changes observed with the individual components alone. The controlled trials focused on short-term follow-up durations, meaning limited information is available for outcomes observed over many years.

---

Research Evidence: Adults Already Using Basal Insulin

The second main set of studies involves adults who were already using basal insulin therapy and met the study criteria for inadequate glycemic control. These studies also used short-term (30-week) RCTs designed to compare the fixed combination against continued basal insulin alone. The primary focus was assessing changes in the A1C biomarker and monitoring Body Weight. Research described patterns where the A1C biomarker was evaluated in comparison to basal insulin used alone. Data are insufficient for patients already using prandial (mealtime) insulin, and the long-term effects on specific cardiovascular outcomes have not been the direct focus of these trials.

---

Evidence in Specific Patient Populations and Research Gaps

Research has explored the effects in subgroups like older adults (age 65 and up). However, data for certain groups remain insufficient. For instance, the combination was not studied for use in patients under 18 years of age or in individuals with severe renal or hepatic impairment. The major evidence gaps include the limited information for long-term outcomes and a lack of comparative evidence against other injectable combination therapies. The findings describe group patterns, and research does not determine whether an individual will respond similarly to the observed study patterns.

Storage and Disposal of Soliqua 100/33

Official labeling defines specific storage requirements to maintain product stability.

Storage Requirements

Condition	Unopened Pens	In-Use Pens (After First Use)
Temperature	Refrigerate (36 F to 46 F / 2 C to 8 C)	Room temperature, below 77 F (25 C)
Freezing	Do not freeze. Discard if frozen.	Do not freeze.
Light Protection	Store in original carton.	Store with pen cap on.
Shelf-Life	Until expiration date.	Discard 28 days after first use.

Used pens must not be put back in the refrigerator after initial use. The pen must not be stored with the needle attached.

Disposal Instructions

All Soliqua 100/33 pens and used needles must be kept out of the sight and reach of children. Used pens and needles must be placed immediately in an FDA-cleared sharps disposal container and must not be thrown into household trash. Final disposal of the sharps container must follow local community guidelines.